RYTM Rhythm Pharmaceuticals Inc

$100.66

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.

Website: https://rhythmtx.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1649904
Address
222 BERKELEY STREET, 12TH FLOOR, BOSTON, MA, US
Valuation
Market Cap
$3.90B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
179.64
Performance
EPS
$-4.34
Dividend Yield
—
Profit Margin
-200.30%
ROE
-155.90%
Technicals
50D MA
$54.76
200D MA
$53.11
52W High
$68.58
52W Low
$35.17
Fundamentals
Shares Outstanding
63M
Target Price
$78.33
Beta
2.32

RYTM EPS Estimates vs Actual

● Estimated
● Actual

RYTM News & Sentiment

Nov 08, 2025 • Motley Fool SOMEWHAT-BULLISH
Rythm Pharmaceuticals' ( RYTM ) Chief Technical Officer Sells 9,748 Shares for $1.1 Million
On November 3, 2025, Chief Technical Officer Joseph Shulman of Rhythm Pharmaceuticals ( NASDAQ:RYTM ) exercised 9,748 options and immediately disposed of all underlying shares in an open-market transaction, as disclosed in this SEC Form 4 filing.Transaction value based on SEC Form 4 weighted ...
Nov 07, 2025 • GlobeNewswire NEUTRAL
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® ( setmelanotide ) for Patients with Acquired Hypothalamic Obesity
-- FDA sets updated PDUFA goal date of March ...
Nov 05, 2025 • Benzinga NEUTRAL
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® ( setmelanotide ) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
BOSTON, Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it has entered into Product Listing ...
Nov 04, 2025 • Zacks Commentary NEUTRAL
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q3 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.89% and +2.11%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 29, 2025 • Zacks Commentary NEUTRAL
Royalty Pharma ( RPRX ) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oct 28, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Rhythm Pharmaceuticals, Inc. ( RYTM ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sentiment Snapshot

Average Sentiment Score:

0.145
50 articles with scored sentiment

Overall Sentiment:

Neutral

RYTM Reported Earnings

Aug 05, 2025
Jun 30, 2025 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.75
  • Estimate: $-0.67
  • Whisper: —
  • Surprise %: -11.9%
May 07, 2025
Mar 31, 2025 (Pre market)
1.35 Surprise
  • Reported EPS: $-0.81
  • Estimate: $-2.16
  • Whisper: —
  • Surprise %: 62.5%
Feb 26, 2025
Dec 31, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.72
  • Estimate: $-0.73
  • Whisper: —
  • Surprise %: 1.4%
Nov 05, 2024
Sep 30, 2024 (Post market)
0.07 Surprise
  • Reported EPS: $-0.73
  • Estimate: $-0.80
  • Whisper: —
  • Surprise %: 8.8%
Aug 06, 2024
Jun 30, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.69
  • Estimate: $-0.71
  • Whisper: —
  • Surprise %: 2.8%
May 07, 2024
Mar 31, 2024 (Pre market)
-0.19 Surprise
  • Reported EPS: $-2.35
  • Estimate: $-2.16
  • Whisper: —
  • Surprise %: -8.8%
Feb 22, 2024
Dec 31, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.70
  • Estimate: $-0.70
  • Whisper: —
  • Surprise %: 0.0%
Nov 07, 2023
Sep 30, 2023 (Pre market)
-0.02 Surprise
  • Reported EPS: $-0.76
  • Estimate: $-0.74
  • Whisper: —
  • Surprise %: -2.7%
Aug 01, 2023
Jun 30, 2023 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.82
  • Estimate: $-0.79
  • Whisper: —
  • Surprise %: -3.8%

Financials